Statin therapy depresses fat metabolism in older individuals.

OBJECTIVE: Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG CoA] reductase inhibitors) reduce blood lipoproteins and reduce the risk of cardiovascular events. However, they may reduce fat metabolism. This study tested the hypothesis that total body fat oxidation is reduced by statins in older subjects and the reduction is not due to substrate availability. METHODS: A total of 14 elderly patients (71 ± 6 years) on statin therapy were compared with 14 matched elderly controls (75 ± 7 years). Subjects were tested for respiratory exchange ratio (RER) during both maximal and submaximal sustained (70% Vo(2max)) exercise to voluntary exhaustion. Blood samples were drawn for lipoprotein analysis and substrate availability. RESULTS: RER was significantly higher in subjects taking statins during both the max and submax tests, indicating reduced fat oxidation. Blood lipoprotein levels after a fast were not different between the statin and control groups. Levels of glucose, lactate, or triglyceride were not different between groups; however, free fatty acid levels were elevated by exercise in the statin group. Fat oxidation was significantly reduced in older subjects taking statin drugs that were not associated with diet, exercise, and fitness, which were matched between groups, nor availability of fat from the blood, which was higher in the statin group. CONCLUSION: Although statin therapy normalizes blood lipoproteins, it reduced fat metabolism in older individuals, which cannot be a result of lower availability from blood.

Isocapnic hyperpnea training improves performance in competitive male runners.

The effects of voluntary isocapnic hyperpnea (VIH) training (10 h over 4 weeks, 30 min/day) on ventilatory system and running performance were studied in 15 male competitive runners, 8 of whom trained twice weekly for 3 more months. Control subjects (n = 7) performed sham-VIH. Vital capacity (VC), FEV1, maximum voluntary ventilation (MVV), maximal inspiratory and expiratory mouth pressures, VO2max, 4-mile run time, treadmill run time to exhaustion at 80% VO2max, serum lactate, total ventilation (V(E)), oxygen consumption (VO2) oxygen saturation and cardiac output were measured before and after 4 weeks of VIH. Respiratory parameters and 4-mile run time were measured monthly during the 3-month maintenance period. There were no significant changes in post-VIH VC and FEV1 but MVV improved significantly (+10%). Maximal inspiratory and expiratory mouth pressures, arterial oxygen saturation and cardiac output did not change post-VIH. Respiratory and running performances were better 7- versus 1 day after VIH. Seven days post-VIH, respiratory endurance (+208%) and treadmill run time (+50%) increased significantly accompanied by significant reductions in respiratory frequency (-6%), V(E) (-7%), VO2 (-6%) and lactate (-18%) during the treadmill run. Post-VIH 4-mile run time did not improve in the control group whereas it improved in the experimental group (-4%) and remained improved over a 3 month period of reduced VIH frequency. The improvements cannot be ascribed to improved blood oxygen delivery to muscle or to psychological factors.